DENVER, Feb. 17, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group, Inc., ( CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in…


Previous articleField Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results
Next articleMindMed’s LSD Neutralizer Study Begins